0811 GMT - Novartis is set to overcome a wave of patent expirations during 2025, Deutsche Bank analyst Emmanuel Papadakis says in a note. The Swiss pharma giant surprised with its margin performance in the last quarter and its 2025 outlook that came ahead of analysts expectations, he says. While some of the 4Q revenue beat was attributed to rebates, Novartis appears well-positioned to continue exceeding market expectations, the analyst says. Deutsche Bank lifts back the stock rating to buy from hold, which had been previously nudge down due to patent expiry worries. (helena.smolak@wsj.com)
(END) Dow Jones Newswires
February 04, 2025 03:12 ET (08:12 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。